Translatum Medicus is focused on developing innovative treatments for dry Age-Related Macular Degeneration (AMD), a leading cause of irreversible blindness. Their approach targets the innate immune system, specifically the cellular arm involving ocular phagocytes, particularly macrophages. These cells play a crucial role in maintaining retinal health and are implicated in the progression of AMD. The company’s lead candidate, TMi-018, is a first-in-class transcriptional modulator that aims to regulate macrophage activity by reducing the transcription of DNA to RNA, thereby influencing multiple downstream proteins. This novel mechanism distinguishes TMi-018 from traditional therapies that typically target individual proteins.

The company emphasizes the importance of understanding the complex genetic and environmental factors associated with AMD, including lifestyle choices and genetic predispositions related to innate immunity and tissue remodeling. By focusing on the transcriptional regulation of macrophages, Translatum Medicus aims to slow the progression of geographic atrophy, a significant complication of dry AMD. Their mission is to efficiently translate scientific discoveries into clinical applications, addressing the urgent need for effective treatments in a field that currently lacks viable options for patients suffering from this degenerative retinal disorder.

Canada

Translatum Medicus Inc is a preclinical drug development company focused on macrophage modulation to treat blinding eye disease, with a patented lead drug candidate, TMi-018 for the treatment of dry Age-Related Macular Degeneration (AMD). 

Translatum is based in the Johnson & Johnson Innovation Incubator JLABS@Toronto, and has been increasingly gaining traction as one of the most innovative early stage ophthalmic biotech companies.

1336 Suite 1300 661 University Avenue, Toronto, Ontario, CA, M5G 0B7

Translatum Medicus

Company Details